Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
11
01
2022
received:
06
08
2021
accepted:
21
02
2022
pubmed:
13
3
2022
medline:
13
4
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
Subsequent vascular events are common after acute ischemic stroke during hospitalization. This study aimed to analyze the effectiveness of combination therapy with clopidogrel and aspirin among mild-to-moderate ischemic stroke patients treated within 72 h on the basis of a high-intensity dose of statins. In a retrospective and multicenter cohort study, acute (within 72 h of onset) mild-to-moderate stroke patients were divided into aspirin and clopidogrel-aspirin groups on the basis of a high-intensity dose of statin therapy. The primary outcome was compound vascular events during hospitalization. Cox's proportional hazards model was used to assess differences, with the study center as a random effect. Among the 506 patients meeting the eligibility criteria, all subjects received a high-intensity dose of statins, including 20 mg rosuvastatin or 40 mg atorvastatin while in the hospital. In an unadjusted analysis, compound vascular events occurred in 7.2% of patients in the clopidogrel-aspirin group compared with 13.7% of those in the aspirin group (p = 0.022). In a Cox proportional hazards regression analysis, clopidogrel-aspirin was associated with a lower risk of compound vascular events (hazard ratio [95% CI], 0.47 [0.25-0.87]; p = 0.017) and ischemic vascular events (p = 0.008). Moderate and severe hemorrhage occurred in four patients (1.07%) in the clopidogrel-aspirin group and three patients (2.30%) in the aspirin group (p = 0.626). In this study based on high-intensity statin therapy, clopidogrel-aspirin reduced the risk of compound vascular events and did not increase the risk of hemorrhage during patients' hospitalization after mild-to-moderate ischemic stroke within 72 h.
Identifiants
pubmed: 35278046
doi: 10.1002/acn3.51541
pmc: PMC8994979
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-514Informations de copyright
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Int J Stroke. 2013 Aug;8(6):479-83
pubmed: 23879752
Stroke. 2010 Apr;41(4):732-8
pubmed: 20181679
N Engl J Med. 2018 Jul 19;379(3):215-225
pubmed: 29766750
N Engl J Med. 2020 Jul 16;383(3):207-217
pubmed: 32668111
N Engl J Med. 1993 Sep 2;329(10):673-82
pubmed: 8204123
Stroke Vasc Neurol. 2019 Jun 29;4(3):158-164
pubmed: 31709123
Lancet. 2018 Mar 3;391(10123):850-859
pubmed: 29274727
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
N Engl J Med. 2016 Apr 21;374(16):1533-42
pubmed: 27096581
Int J Stroke. 2006 Aug;1(3):158-9
pubmed: 18706036
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006474
pubmed: 33201737
N Engl J Med. 2016 Jul 7;375(1):35-43
pubmed: 27160892
JAMA Neurol. 2018 Jun 1;75(6):711-719
pubmed: 29582084
Stroke. 2018 Dec 7;:STROKEAHA118022691
pubmed: 30580722
JAMA. 2016 Jul 5;316(1):70-8
pubmed: 27348249
N Engl J Med. 2013 Jul 4;369(1):11-9
pubmed: 23803136
N Engl J Med. 2020 Jan 2;382(1):81-82
pubmed: 31738482
Neurology. 2015 Sep 29;85(13):1154-62
pubmed: 26330567
N Engl J Med. 2006 Aug 10;355(6):549-59
pubmed: 16899775
Stroke. 2019 Nov;50(11):3147-3155
pubmed: 31587655
Lancet Neurol. 2010 May;9(5):489-97
pubmed: 20335070
N Engl J Med. 2020 Jan 2;382(1):9
pubmed: 31738483